[Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer].
A retrospective analysis included 63 patients with urothelial cancer. Untreated tumor tissue sampled in the course of primary surgery was examined by immunostaining procedure. After surgery, superficial tumors were treated with intravesical chemotherapy, invasive cancer--chemoradiotherapy. Overall survival was significantly higher in cases of low expression of antigen Ki-67 and gene-suppressor p53 while relapse-free survival in patients without HER-2 expression was significantly higher than in cases of overexpression.
Masliukova
E A
EA
Pozharisskiĭ
K M
KM
Karelin
M I
MI
Startsev
V Iu
VIu
Ten
V P
VP
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000737:chemistry* / Q000175:diagnosis* / Q000628:therapy; D018572:Disease-Free Survival; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012189:Retrospective Studies; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000175:diagnosis* / Q000628:therapy; D019459:Urothelium / Q000737:chemistry / Q000473:pathology
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53